Navigation Links
Maine Biotechnology Services-USDA-ARS Partnership Provides Monoclonal Antibodies to Aid in the Containment of Rift Valley Fever Virus
Date:11/12/2013

Portland, Maine (PRWEB) November 12, 2013

In July 2012, Maine Biotechnology Services entered into a partnership with Dr. Scott McVey, supervisor of the USDA-Agricultural Research Service (USDA-ARS) Arthropod Borne Animal Disease Research Unit, with the objective of developing monoclonal antibodies to support ongoing research efforts to advance adequate vaccine and rapid detection methods for Rift Valley Fever Virus in Africa. MBS is announcing the release of the first two antibodies resulting from that partnership; a functioning matched pair demonstrating specificity to the nucleocapsid protein of the virus. The antibodies have applications as detection reagents for circulating antigen, mosquito carriers, or as components of differentiation of infected and vaccinated animals (DIVA) assays. In the final phase of validation for the antibodies, Dr. McVey intends to deliver them to USDA-ARS partnered laboratories in South Africa and other endemic African nations for assay development with clinical samples. Future goals of the MBS-USDA-ARS Rift Valley Fever program include the development of antibodies to the Gn and NSs proteins to support vaccine programs.

About Rift Valley Fever Virus: Rift Valley Fever is a devastating virus transmitted by mosquitoes that affects both animals and humans. The disease results in significant economic losses due to death and abortion in RVFV infected livestock. Originating in the Rift Valley of Kenya, outbreaks of the virus now occur in all areas of sub-Saharan and North Africa. Cases have also been confirmed in Yemen and Saudi Arabia, causing widespread concern about the vulnerability of parts of Asia and Europe involved in livestock trade with Africa.

About Maine Biotechnology Services: Maine Biotechnology Services is a premier provider of antibody services, from design and development to production and characterization. MBS extends the creativity and experience necessary for the most complex hybridoma development projects. A wide variety of tools are utilized by MBS to allow customers the opportunity to refine clone selection early in a project, and to support prototype assay validation. Collaboration opportunities combine 25 years of custom hybridoma development experience at MBS with academic expertise on a target of shared interest.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11321207.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Maine Selects Advanced Kiosks as Supplier for Statewide Initiative
2. Maine Law Further Protects Health Care Providers in Preferred Provider Arrangements
3. Classe Wines Announces Availability of 2007 Domaine Du Pourra La Reserve Gigondas
4. Classe Wines Offers 2008 Pinot Noir Domaine Jean-Michel Guillon Les Crais in Limited Quantity
5. 2000 Domaine Barat Chablis Premier Cru "Les Fourneaux" Available in Limited Quantity from Classe Wines
6. Zane Benefits Publishes New Information on Maine Health Insurance Exchange
7. Premier Cru, Gem of French Winemaking Arrives in the United From Domaine Bzikot Made Available by Classe Wines
8. Policy Meets Practice at 23th Annual Maine Geriatrics Conference
9. University of Maine Football Completes Ground-Breaking Team Leadership and Emotional Intelligence Training Program
10. Vein Healthcare Center in South Portland, Maine Hosts Varicose Vein Seminar
11. High Schoolers Can 'Smile' While Exploring Dental Careers at Summer Camp in Maine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... human performance, is proud to announce that it has received 510(k) clearance from ... the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling ...
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... BC (PRWEB) , ... April 25, 2017 , ... The ... from Richmond, BC, who live with dental fear and require sedation to receive dental ... at ease during various procedures, from hygienic cleanings to oral surgery, at their ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
(Date:4/25/2017)... Clara, CA (PRWEB) , ... April 25, 2017 ... ... announces the addition of predictive analytics to its patient care management module. Using ... compliance even before a patient has been initiated on continuous positive airway pressure ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
Breaking Medicine Technology: